Results 71 to 80 of about 136,524 (172)

Purification and concentration of model viruses using single‐pass tangential flow filtration

Biotechnology Progress, EarlyView.
Single‐pass TFF was developed for an enveloped and non‐enveloped virus for use in continuous downstream purification processes. Enveloped virus was concentrated and purified. Abstract The vaccine and viral vector industry is growing at an accelerated rate.
Luis Alberto Mejía‐Manzano, Lynn Manchester, Grace Wallis, Kan Wang, Bruce P. Lee, Michael Betenbaugh, Caryn L. Heldt   +6 more
wiley   +1 more source

Vaccination contre la FCO en France et en Europe

La vaccination contre la Fièvre Catarrhale Ovine (FCO) est un défi à chaque fois qu’un nouveau sérotype émerge, car il n’existe que peu, voire pas de protection croisée d’un sérotype à un autre, du fait d’une très forte variabilité génétique du virus ...
Pierre Bessière
core   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

In‐line Raman spectroscopy real‐time glucose prediction method for commercial pneumococcal vaccine drug substance fermentation manufacturing process control

Biotechnology Progress, EarlyView.
Abstract Traditional off‐line analysis methods to quantify residual metabolite concentrations in a drug substance fermentation process consume valuable time, require costly resources, and demand potentially hazardous manual operations when working with pathogenic biological organisms.
Griffin P. Thomas, Brian C. Marks, Barbara B. Alvarado‐Hernandez, Matthew Woodling, James O'Connor, Roberto Ortiz, John Higgins, Jon Shanter   +7 more
wiley   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

Biotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing, Tomoki Igi, Daniel Strauss   +2 more
wiley   +1 more source

Overall and serotype-specific dengue virus transmission intensity in Mexico, 2016-2023: A modelling study of case-notification data. [PDF]

PLoS Med
Simmons OS, Vicco A, Martínez-Vega RA, Ramos-Castañeda J, Dorigatti I.   +4 more
europepmc   +1 more source

High‐throughput development and scale‐up of recombinant adeno‐associated virus 5 anion‐exchange chromatography for high‐purity capsid separation

Biotechnology Progress, EarlyView.
High‐throughput anion‐exchange chromatography process development enables scalable purification of high‐purity recombinant adeno‐associated virus capsids. Abstract Recombinant adeno‐associated virus (rAAV) production commonly yields a high proportion of empty and partially filled capsids, necessitating downstream purification to enrich full capsids ...
Kevin Vera, Ivan Gajic, Praveen Kusumanchi, Angela Andaluz, Gabrielle Dela Pena, Clifford A. Froelich, Elizabeth Higgins, Jennifer Johnston, Seyed Pouria Motevalian   +8 more
wiley   +1 more source

Optimizing adult pneumococcal vaccination in India: Evidence from serotype surveillance. [PDF]

Lung India
Isaac TB, Gurumoorthy M, Koul PA, Ratnavelu VK, Veeraraghavan B.   +4 more
europepmc   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

A reusable model of pangenome selection informs optimal surveillance strategies over vaccine introductions. [PDF]

Genome Med
Lorenz LJ, Hellewell J, Horsfield ST, Russell MJ, Shrestha S, Pollard AJ, Bentley SD, Lo SW, Colijn C, Croucher NJ, Lees JA.   +10 more
europepmc   +1 more source